Fig. 2

Molecular monitoring of BCR-ABL1 levels of patient 24 since diagnosis. The patient achieved a DMR after 30 months of imatinib therapy and was in MR^4.5 (undetectable disease) at the time of TKI discontinuation. After therapy interruption, the patient showed oscillations in BCR-ABL1 levels until she achieved a MR^5.0 with undetectable disease 50 months after imatinib discontinuation. In this patient, no therapeutic intervention directed to CML was performed since TKI discontinuation